Abstract
Published on:August 2022Journal of Young Pharmacists, 2022; 14(3):283-288Original Article | doi:10.5530/jyp.2022.14.56 Authors:Krishna Yadav1,2, Deependra Singh1, Manju Rawat Singh1, Ajazuddin3, Amit Alexander4, Sunita Minz5, Madhulika Pradhan6, Kamal Shah7, Nagendra Singh Chauhan81University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, INDIA.2Raipur Institute of Pharmaceutical Education and Research, Sarona, Raipur, Chhattisgarh, INDIA.3Department of Pharmaceutics, School of Pharmacy and Technology Management, SVKM’s, NMIMS, Shirpur, Maharashtra, INDIA.4National Institute of Pharmaceutical Education and Research (NIPER-G), Ministry of Chemicals and Fertilizers, Government of India, SilaKatamur (Halugurisuk), Changari, Kamrup, Guwahati, Assam, INDIA.5Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, INDIA.6Rungta College of Pharmaceutical Sciences and Research, Kohka, Kurud Road, Bhilai, Chhattisgarh, INDIA.7GLA University, Institute of Pharmaceutical Research, Mathura, Uttar Pradesh, INDIA.8Drugs Testing Laboratory, Avam Anusandhan Kendra (State Government Lab of AYUSH), Government Ayurvedic College, Raipur, INDIA Abstract: Background: The Severe Acute Respiratory Coronavirus (SARS-CoV-2) has emerged in a variety of forms since its first appearance in early December 2019. The Omicron variation (B.1.1.529) was recently confirmed as a relatively new Variant of Concern (VOC). There are several mutations in this S-protein, making it an exclusively lethal version of the protein. Omicron variants feature multiple mutations clustered in a region of S protein that is the principal target of antibodies, and these mutations may have an impact on the binding affinities of antibodies to the S protein, as demonstrated by structural analysis. Materials and Methods: Google, Sciencedirect, Web of science, and Research Gate databases have been explored for potentially existing research to obtain the most emerging trends and up-to-date metadata on various perspectives of Omicron variants. Conclusion: There is evidence that the Omicron variant’s mutations may interfere with antibody binding in people who have been exposed to the SARS-CoV-2 virus in the past. At the moment, there is very little information on the Omicron version. Therefore, mutation dispersion evaluations, evolutionary links to previous variants, and putative structural effects on antibody binding effects are all explored in this work. Results: In the current state of pandemic crises, the comprehension of Omicron will pave a path for healthcare professionals to treat infectious conditions very well.Keywords: SARS-CoV-2 virus, Mutations, Omicron, Vaccines, Antibody.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
